Results support beginning pivotal Phase 3 clinical trial in Q2 2016
Sanofi and its specialty care global business unit Sanofi Genzyme today presented data from NEO1, its Phase 1/2 clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease. The safety and efficacy data from this study, which were presented at WORLDSymposium 2016 in San Diego, CA, support further development of the therapy. Sanofi Genzyme plans to begin enrolling patients in a pivotal Phase 3 trial for neoGAA in Q2 2016...
Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.